| 1537877-82-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机碘化物
• CAS: 1537877-82-9
• 化学式: C₈H₁₅I
• 分子量: 238.112
• InChiKey: GCCFHHREIHRJQH-ZKCHVHJHSA-N

物化性质

• 沸点：
  224.7±9.0 °C(Predicted)
• 密度：
  1.431±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.25
• 重原子数：
  9.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

反应信息

• 作为产物：
  描述：

  (4-甲基环己-3-烯-1-基)甲醇 在 咪唑 、 叔丁基过氧化氢 、 Mn(dpm)₃ 、 苯硅烷 、 碘 、 三苯基膦 作用下， 以 癸烷 、 二氯甲烷 、 异丙醇 为溶剂， 反应 0.75h， 生成 、
  参考文献：
  名称：

  Simple, Chemoselective Hydrogenation with Thermodynamic Stereocontrol

  摘要：

  Few methods permit the hydrogenation of alkenes to a thermodynamically favored configuration when steric effects dictate the alternative trajectory of hydrogen delivery. Dissolving metal reduction achieves this control, but with extremely low functional group tolerance. Here we demonstrate a catalytic hydrogenation of alkenes that affords the thermodynamic alkane products with remarkably broad functional group compatibility and rapid reaction rates at standard temperature and pressure.

  DOI：

  10.1021/ja412342g

文献信息

• VLA-4 INHIBITORY DRUG
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1961750B1

  公开（公告）日：2013-09-18
• [EN] FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS<br/>[FR] HETEROCYCLES A CINQ CHAINONS UTILISES COMME INHIBITEURS DE LA SERINE PROTEASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005123050A2

  公开（公告）日：2005-12-29

  The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): (I) [INSERTCHEMICAL STRUCTURE HERE] (V)[INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.